Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 and six-month financial results ended June 30, 2026 announced August 5, 2026.
LIFECORE BIOMEDICAL, INC. DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and six-month financial results ended June 30, 2026 announced August 5, 2026
- Detailed results and management commentary available in Exhibit 99.1
- Earnings disclosure signals new operating performance information for investors
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished under Reg FD, providing market-facing information to investors
- Exhibit 99.2 contains the substantive presentation materials and likely details management’s current messaging
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $34.2M, net loss $(6.2)M, and Adjusted EBITDA $8.6M
- 2026 guidance reaffirmed: revenue $120-$125M and Adjusted EBITDA $20.5-$25M
- Liquidity $38.8M at June 2026, including $17.2M cash and $21.6M revolver availability
- Six new Q2 programs and 13 wins over 12 months strengthen future commercial visibility
- Pipeline targets 11 launches in 2027-2028 with estimated $150-$200M incremental peak revenue potential, not risk-adjusted
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIFECORE BIOMEDICAL, INC. DE 8-K filings
Get the next LFCR 8-K as it lands
Follow LFCR for push alerts, or ask the research agent what this filing means.